is jardiance a glp-1 receptor GLP1-GIP co-agonists: promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Frontiers | GLP-1 Receptor Agonists:

doi: 10.1038/s41591-025-03774-9, 95 MathesC

Hard No

PEPTIDE THERAPY CLINIC EL PASO, TX 20 targeted peptide protocols BPC-157, Sermorelin, CJC-1295/Ipamorelin, GHK-Cu, Tesamorelin, PT-141, Thymosin Alpha-1, and more prescribed and monitored by Celeste Cisneros, FNP-BC

In an animal model of leukopenia, melatonin helped maintain hematopoietic function, leading the researchers to conclude o ur results indicate that overall [melatonin] exerts a remarkable countering activity towards leukopenia and anemia (Pacini 2009)

Obstructive Sleep Apnea SURMOUNT-OSA trials investigated GLP2 in adults with moderate-to-severe obstructive sleep apnea and obesity: Significant improvements in apnea-hypopnea index (AHI) from baseline Benefits observed in participants both using and not using positive airway pressure therapy Improvements correlated with weight reduction FDA approval granted in December 2024 for moderate-to-severe OSA treatment Diabetes Prevention Extended follow-up from SURMOUNT-1 assessed diabetes prevention in participants with prediabetes: 94% reduction in progression to type 2 diabetes compared to placebo over 3 years Nearly all participants with prediabetes at baseline converted to normoglycemia Effects diminished during off-treatment follow-up period, indicating ongoing treatment benefit [CALLOUT BOX Highlighted] Important Context: While GLP2 has demonstrated substantial efficacy in multiple large-scale clinical trials, the majority of data comes from industry-sponsored studies with relatively short follow-up periods (40-72 weeks for most trials)